Migraine - Xconomy

by in

Entry	Author	Date	Location
Alder Biopharma Snags $38M To Charge Ahead With Antibody Drugs	Luke Timmerman	04/19/12	Seattle
The Year in Seattle Biotech: Lots of Acquisitions, Few New Startups	Luke Timmerman	12/22/11	Seattle
Arteaus, With $18M From Atlas and OrbiMed, Forges Ahead on Migraine-Prevention Drug	Arlene Weintraub	10/19/11	Boston
Zogenix Strategy Unfolds as it Unveils Plans for Next Drug-and-Device Combo	Bruce V. Bigelow	07/19/11	San Diego
Dendreon Moves Across Town, SeaGen Files FDA App, Alder Takes Road Less Traveled, & More Seattle Life Sciences News	Luke Timmerman	03/03/11	Seattle
Alder Steers Next Antibodies To Unusual Places: Treating Migraines and High Cholesterol	Luke Timmerman	03/02/11	Seattle
Saagara Planning New Health Apps, Getting Advice from Ted Dacko, Former HealthMedia Chief	Ryan McBride	12/14/10	Detroit
Stopping Migraines Before They Hurt: NeurAxon Pursues New Pain Drug	Luke Timmerman	02/02/09	Boston
Torrey Pines Therapeutics Permitted to Begin Phase III Trial of Migraine Drug	Luke Timmerman	10/01/08	San Diego
Page 1 of 1

Xconomy National